Navigation Links
Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
Date:2/17/2011

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones.  

"2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein occlusion, and one with ARCALYST® for the prevention of gout flares in patients initiating uric-acid lowering therapy," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "We expect regulatory applications to be filed in the first half of 2011 for marketing approval in the U.S. and Europe for VEGF Trap-Eye in wet AMD.  We also look forward to reporting results from additional Phase 3 trials in central retinal vein occlusion and gout and from two Phase 3 trials with aflibercept in cancer."

"In anticipation of potential product approvals," Dr. Schleifer added, "we are continuing to build our commercialization capabilities.  We are also advancing our earlier-stage pipeline which currently includes eight fully-human monoclonal antibodies in clinical development for the treatment of various diseases and conditions including elevated LDL cholesterol, rheumatoid arthritis, atopic dermatitis, and cancer.  We anticipate Phase 2 data from some of these programs in 2011."

"We entered 2011 in a strong financial position to support our development and commercialization activities," commented Murray A. Goldberg, Chief Financial Officer, "with approximately $627 million in cash and securities, following a successful public offering of Common Stock in October 2010."

Clinical Programs UpdateVEGF Trap-Eye (aflibercept opht
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ALTO, Calif. , Sept. 30, 2014 /PRNewswire/ ... investment group focused on supporting promising emerging biotech, ... has been named the Top Angel Investment Group ... Insights as the best performer out of 370 ... included: historical performance, network strength (connections), selection aptitude ...
(Date:9/30/2014)... 2014  Millennium Healthcare Inc. ( MHCC ) today announced ... a sales, marketing and distribution agreement with MDbizWorx. ... based provider of ancillary medical services that serves ... hospitals through a seasoned national marketing and sales ... Purchasing Accounts that include a network database of ...
(Date:9/30/2014)... DUBAI , UAE, September 30, 2014 ... Pharmacy branch openings to feature in-store events will change ...   Revolutionizing the way we use and ... customers interact with pharmacies. By catering to the very ... has designed a calendar of in-store events with various ...
Breaking Medicine Technology:Life Science Angels Ranked the Top Angel Investment Group in the U.S. 2Life Science Angels Ranked the Top Angel Investment Group in the U.S. 3Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 2Millennium Healthcare Secures New Sales, Marketing and Distribution Agreement 3Health First Pharmacy Redefines 'Pharmacy Retail Experience' 2Health First Pharmacy Redefines 'Pharmacy Retail Experience' 3
... 11 In conjunction with its fourth quarter 2009 earnings release (expected ... (NYSE: CVD ) is pleased to invite you to listen ... the Internet on Thursday, January 28, 2010 at 9:00 a.m. ET. , ... and Slide Presentation, When: January 28, 2010, 9:00 ...
... 11 BD (Becton, Dickinson and Company) (NYSE: BDX ... its first fiscal quarter 2010 earnings conference call on Thursday, January ... press release detailing the quarter,s earnings earlier that morning. , The ... accessible through BD,s website at www.bd.com/investors and will be ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2
(Date:9/30/2014)... September 30, 2014(BRONX, NY)Medications are the leading cause of ... analysis of death certificates from 1999 to 2010, conducted ... and Albert Einstein College of Medicine of Yeshiva ... Journal of Allergy and Clinical Immunology , also ... was particularly high among older people and African-Americans and ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... as a free introduction to SurvivalLife.com along with a free ... caught the attention of Shane Michaels, prompting an investigative review. ... most well-known people in the survival and preparation niche, and ... all of the great classes and survival products that Joe ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Hospice ... its annual “In Celebration” gala, honoring three outstanding ... mission of striving to provide extraordinary and dignified ... facing a serious or life-limiting illness. , The ... in Rye, NY and recognized William (Bill) J. ...
(Date:9/30/2014)... 2014 A group of Americans is headed ... epidemic that, left unchecked, could create a catastrophic, global pandemic. ... to Africa. John Rogers, the Executive Director the Eugene Bell ... fight a disease most think mankind conquered long ago: tuberculosis. ... ago is on the comeback in several countries - what’s ...
Breaking Medicine News(10 mins):Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2
... Center at the University of California, San Diego, the University ... how a gene alteration can lead to the development of ... compound that could staunch the cancer,s growth. , The researchers, ... UC San Diego School of Medicine, have shown that when ...
... For decades, researchers have evaluated the thermal performance of ... current interest is how to address the burns received ... with fire - called stored heat burns. Researchers at ... and measurement protocol that allow firefighter suits to be ...
... to Enhance Tobacco-Related Research WASHINGTON, ... for Tobacco Research and Policy Studies at the ... Center at Georgetown University Medical Center ... Cancer Control Consortium. The consortium, formally agreed to ...
... nutritional benefits; Packaging now more environmentally responsibleNEW YORK, April ... the enhanced water category, PepsiCo (PEP) is re-launching ... beverage designed to help hydrate and nourish the body,s ... Propel is available in a variety of great-tasting ...
... findings at AMCP Conference in AprilST. PAUL, Minn., ... (Prime) revealed a significant reduction in inappropriate prescription ... drug utilization review (RetroDUR) program paired with a ... recently published in the American Journal of Geriatric ...
... recognition of April as National Autism Awareness Month, LoJack Corporation (Nasdaq: ... http://www.lojack.com/knowledge/Documents/AutismAwarenessMonth.mp3 ) that provided valuable information ... The rising incidence of autism in the ... of caring for an autistic child , ...
Cached Medicine News:Health News:Reversing effects of altered enzyme may fight brain tumor growth 2Health News:NC State develops new test method to measure stored heat in firefighter suits 2Health News:American Legacy Foundation(R) and Georgetown University Medical Center Create Research Collaboration 2Health News:American Legacy Foundation(R) and Georgetown University Medical Center Create Research Collaboration 3Health News:American Legacy Foundation(R) and Georgetown University Medical Center Create Research Collaboration 4Health News:Propel Unveils New Enhanced Experience 2Health News:Propel Unveils New Enhanced Experience 3Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 2Health News:Drug Utilization Review Reveals Potentially Inappropriate Medication Use Among Elderly Population 3Health News:April is National Autism Awareness Month: LoJack Hosts Educational Podcast Featuring Panel of Experts Addressing Autism Issues 2
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Straight shafts with 15 mm long jaws. Serrated handle with polished finish. Smooth jaws....
Straight shafts with 6.5 mm tying platform. Crisscross serrated 1mm tips. Scalloped handle with dull finish....
Smooth tip forceps allow the surgeon to manipulate and smooth the corneal flap in Lasik procedures. Tip angled 10 mm from tip. Manufactured in titanium....
Medicine Products: